Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs.
about
Prevention of intestinal allergy in mice by rflaA:Ova is associated with enforced antigen processing and TLR5-dependent IL-10 secretion by mDCAdenovirus dodecahedron, as a drug delivery vectorImmunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in miceAn influenza A/H1N1/2009 hemagglutinin vaccine produced in Escherichia coliInfluenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protectionDNA-Encoded Flagellin Activates Toll-Like Receptor 5 (TLR5), Nod-like Receptor Family CARD Domain-Containing Protein 4 (NRLC4), and Acts as an Epidermal, Systemic, and Mucosal-AdjuvantDevelopment of universal influenza vaccines based on influenza virus M and NP genes.Preliminary study about sublingual administration of bacteria-expressed pandemic H1N1 influenza vaccine in miniature pigs.Using plant cells as influenza vaccine substrates.Hemagglutinin Sequence Conservation Guided Stem Immunogen Design from Influenza A H3 SubtypeSuperior efficacy of a recombinant flagellin:H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin.Specific recognition of influenza A/H1N1/2009 antibodies in human serum: a simple virus-free ELISA method.Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virusBacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets.Vaccination with Killed but Metabolically Active E. coli Over-expressing Hemagglutinin Elicits Neutralizing Antibodies to H1N1 Swine Origin Influenza A VirusPandemic influenza vaccines - the challenges.Yeast expressed recombinant Hemagglutinin protein of novel H1N1 elicits neutralising antibodies in rabbits and mice.New technologies for influenza vaccines.Cell-free production of trimeric influenza hemagglutinin head domain proteins as vaccine antigens.Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in miceSublingual administration of bacteria-expressed influenza virus hemagglutinin 1 (HA1) induces protection against infection with 2009 pandemic H1N1 influenza virus.Vaccination against influenza with recombinant hemagglutinin expressed by Schizochytrium sp. confers protective immunity.A baseline process for the production, recovery, and purification of bacterial influenza vaccine candidates.Contrasting roles for TLR ligands in HIV-1 pathogenesis.Lipid motif of a bacterial antigen mediates immune responses via TLR2 signaling.Robust immunity and heterologous protection against influenza in mice elicited by a novel recombinant NP-M2e fusion protein expressed in E. coliMalaria Vaccine Development: Are Bacterial Flagellin Fusion Proteins the Bridge between Mouse and Humans?Bacterially produced recombinant influenza vaccines based on virus-like particles.Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes.Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys.An avian influenza A (H7N9) virus vaccine candidate based on the fusion protein of hemagglutinin globular head and Salmonella typhimurium flagellinImmunopotentiation of Different Adjuvants on Humoral and Cellular Immune Responses Induced by HA1-2 Subunit Vaccines of H7N9 Influenza in MiceGlycoconjugate vaccine strategies for protection against invasive Salmonella infections.Immunogenicity and protective efficacy of a dual subunit vaccine against respiratory syncytial virus and influenza virusPhase 1 Safety and Immunogenicity Study of a Quadrivalent Seasonal Flu Vaccine Comprising Recombinant Hemagglutinin-Flagellin Fusion Proteins.Baculovirus vector as a delivery vehicle for influenza vaccines.Mucosal and Systemic Immune Responses to Influenza H7N9 Antigen HA1-2 Co-Delivered Intranasally with Flagellin or Polyethyleneimine in Mice and Chickens.Adjuvanted influenza vaccines.Prophylactic and therapeutic implications of toll-like receptor ligands.Vaccines based on structure-based design provide protection against infectious diseases.
P2860
Q27323956-FE47148C-5B73-4458-BB8A-2CCD9CC6599AQ28475489-ADE3C848-F749-41FD-ADDE-FD4A11766113Q28743887-355D6756-082B-4B56-9DBE-DB136DC3FE60Q28750246-FBB5F3F9-8CAB-4DC1-97C9-556722321609Q30209769-8771E90F-8959-45CE-8FA1-707FEBA90BB2Q30223578-062EE1C4-6586-4EF8-81EF-50A9171C6A29Q30355116-3AD2986D-AF6A-460F-B2C0-78E07E046602Q30365312-AC0F5011-AA34-40C9-A343-5D2E19EAFDBBQ30375988-F7C558FF-374B-48A5-B2FD-37383BB08ADCQ30376605-BE1CA896-44E1-4482-B3D3-66939BF301ADQ30379493-52473FA7-2381-4447-A0C7-54E032F42971Q30388531-75C66ACF-D696-46F4-BCDF-A3B0F4AC8139Q30391443-5DF684E5-306D-4304-BDE9-ACF0898ECA85Q30396343-89A112EC-11B4-4DB7-A3DE-4CA40D533DB8Q30401849-3BC305EC-86EB-4D78-A939-934FB30FFF69Q30408091-CA05EB0B-EB2F-4DF3-B700-70B0BF7F5F10Q30410094-AD0EFCE3-5DDF-40CE-95E1-5727330664A4Q30411859-11304809-E880-4687-9600-D9EB07EFA5A0Q30418486-5A6D17EE-5A10-4F86-877F-A6F3A91405DFQ30425194-DE1538E8-43D7-45D5-9A79-9EC3FA691128Q30427778-6EF1B02D-E293-4CBF-9CAA-D2F916BD43EFQ30429880-6013933F-D617-43D4-BEF8-04C24E7579C4Q30431659-91A0C319-1070-420F-885F-A61252052516Q33700312-50872D12-2F59-4BD3-9934-ADDED357D627Q33911347-99564E2C-867B-4563-BDD8-035286D36C50Q34533990-7D801189-D657-4C47-9949-1F37B67425EAQ34983659-194D3715-8E43-47D5-8619-0ED0FCBD0C5BQ35048127-44BF6ED9-3D97-4523-B8A4-E2CCADABB422Q35095954-75962129-1521-4891-A527-9300C4375EF7Q35548048-45311A4F-E2CD-4379-9C7D-A3AECF25CFB1Q35749381-A0AEDFBD-0CD3-464D-9B7A-93199FFF5B9EQ35940724-BAFC5708-38EB-4F74-860E-DF47C879D33CQ36184367-15928481-00B0-4012-B68B-7452650520CAQ36592781-69CBBB2E-747D-4F73-8B33-DD49D1C3359BQ36615539-94DD7DE2-404A-4BE9-822D-4C0E18878735Q37434539-EEDC101A-2E04-4D39-B4FE-B92532A246A6Q37737532-C3D8F718-075E-47AE-8BF0-B75129FB913EQ37976540-6797739B-D395-4B8E-8205-FD68D01E35E1Q37989884-71FB75CC-D08D-4E72-A883-1689C2E35285Q38148782-9FF1F6FD-98AB-468D-A967-FCD3F49725A8
P2860
Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Efficacious recombinant influe ...... l pandemic and seasonal needs.
@ast
Efficacious recombinant influe ...... l pandemic and seasonal needs.
@en
type
label
Efficacious recombinant influe ...... l pandemic and seasonal needs.
@ast
Efficacious recombinant influe ...... l pandemic and seasonal needs.
@en
prefLabel
Efficacious recombinant influe ...... l pandemic and seasonal needs.
@ast
Efficacious recombinant influe ...... l pandemic and seasonal needs.
@en
P2093
P2860
P1433
P1476
Efficacious recombinant influe ...... l pandemic and seasonal needs.
@en
P2093
Albert Price
Andrea Jacobs
Gail Maksymiuk
Jim Huleatt
Langzhou Song
Lucia Reiserova
Lynda Tussey
P2860
P356
10.1371/JOURNAL.PONE.0002257
P407
P577
2008-05-21T00:00:00Z